Celgene taps Bluebird, Baylor to develop cancer drugs
This article was originally published in Scrip
Celgene is hoping a small biotech company and Baylor University researchers can help it develop gene therapies that use altered blood cells for fighting cancer.
You may also be interested in...
Excitement around cell therapy has been building in recent years, but companies expect interest to accelerate after Gilead agreed to buy Kite for $11.9bn and Novartis won the first ever CAR-T approval.
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.